Current treatment approaches for diffuse large B-cell lymphoma (Q37132898)

18 August 2017

1 reference

title

Current treatment approaches for diffuse large B-cell lymphoma (English)

1 reference

18 August 2017

Tim Illidge

1

0 references

author name string

Shaun Tolan

series ordinal

2

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

49

1 reference

18 August 2017

4

1 reference

18 August 2017

663-676

1 reference

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

18 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Gene expression profiling in malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Increasing chemotherapy intensity in aggressive lymphomas: a renewal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

State-of-the-art therapeutics: diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701882187

10.1080/10428190701882187

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18398733